Replies to post #553205 on NorthWest Biotherapeutics Inc (NWBO)

[no2koolaid]

hoffmann, just a quick comment to agree with you about a merger between a CDMO and a biopharma company. Bigger picture...

In reverse order: 1) it does not improve the value of NWBO for an ultimate acquisition by a BP. The BPs are not in the CDMO business and would sell it off; which reduces rather than increases the value of NWBO to a BP; and 2) There is no answer to how it improves a partnership because it would not.

I understand the seeming magic of the Advent/NWBO merger resulting in uplisting, but it really is nothing more than financial engineering (alchemy) that, again, does not result in a long term benefit, as that alone, without any RA approvals, would find the share price under attack.

One more thing...I have said this ad nauseam but it remains true for NWBO investors...We do not want a buyout now. We want partnerships and not just any. My guess is Merck's approach to a partnership would be for a limited partnership between the two firms. That would be a mistake, NWBO should not allow themselves to be limited; particularity not if we consider the agnostic potential.

[biosectinvestor]

Agreed Hoffmann. The whole point of using a CDMO and the whole issue for a CDMO is that they are separate businesses. This is being done at a plant owned by NWBO so that they can assume control wherever and whenever they want and so that the company can also be sold with the factory, no need to own a CDMO because that is a cost center, not a profit center. Employees. A large BP doesn’t want to own a CDMO, a CDMO does not want to be owned by a drug manufacturer, that is destructive of their value. You can’t compete with your other customers as a CDMO.

There are so many reasons why that whole notion has never made any sense.